Amid ongoing buyout overtures from Paris-based Sanofi-Aventis, Genzyme announced Monday that it reached an agreement to sell its genetic testing business, Genzyme Genetics, to Laboratory Corporation of America Holdings (LabCorp) for $925 million in cash.

Longtime Genzyme counsel Ropes & Gray advised the Cambridge, Mass.-based company on the deal, with Boston-based M&A partner Chris Comeau leading that firm’s team. Other Ropes lawyers on the deal included corporate partner Paul Kinsella; IP partner David McIntosh; tax and benefits partner Eric Elfman; labor and employment partner Diane Patrick; debt finance partner Tom Draper; and real estate partners Walter McCabe and Peter Alpert in Boston. Antitrust partners Mark Popofsky and Mike McFalls also worked on the deal from Washington, D.C.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]